1 / 72

Review: Surgery for Heart Failure

British Heart Foundation. Review: Surgery for Heart Failure. Ian Ramnarine Cardiac Surgical Research Fellow. Background. End-stage Heart Failure Deaths from CCF Cardiac Rehabilitation Pharmacotherapy Percutaneous Intervention Surgery. Heart transplants by year.

solomon-beach
Download Presentation

Review: Surgery for Heart Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. British Heart Foundation Review:Surgery for Heart Failure Ian Ramnarine Cardiac Surgical Research Fellow

  2. Background • End-stage Heart Failure • Deaths from CCF • Cardiac Rehabilitation • Pharmacotherapy • Percutaneous Intervention • Surgery

  3. Heart transplants by year

  4. PharmacotherapyNew & Old Drugs • ACE Inhibitors • Statins • Beta-blockers • Spironolactone

  5. Percutaneous Intervention • PTCA • Balloon Angioplasty • Stents • Drug-eluting stents • Alcohol injection for HOCM • Trans-myocardial Revascularization

  6. Surgery • Coronary Revascularization • Valvular Surgery • Ventricular Reconstruction for Ischaemic Cardiomyopathy • Mitral Repair for Regurgitation • LV Aneurysm Plication/Resection • Ventricular Remodelling • Post-infarct VSD repair

  7. Ischaemic Cardiomyopathy

  8. LV Aneurysm Plication/Resection

  9. Batista Operation

  10. Nair Operation

  11. Cellular Mechanisms • Genetherapy • Cellular Cardiomyoplasty • Immunoregulation in Transplantation • Tissue Engineering (valves)

  12. Cellular Cardiomyoplasty • HF when a critical number of cardiomyocytes irreversibly lost • Function improved with new cells • Islet cell implantation

  13. Cellular Cardiomyoplasty • Optimal type of donor cells • Mechanism by which cell engraftment improves cardiac function • Optimization of cell survival • Potential benefits of cell transplantation in non-ischemic heart failure

  14. Evidence • Grafted neonatal cardiomyocytes detectable in infarcted areas 6/12 post-transplantation • Sino-Atrial Fetal cells trigger pacemaker activity when conduction system damaged

  15. Issues • Ethics • Availability • Antigenicity • Major risk • Tumor development • Arrhythmias

  16. Skeletal myoblasts • Elastic properties • Direct contribution of grafted cells to improved systolic function • Paracrine effects • Modulates injury response

  17. Bone marrow stem cells • Different cell populations • Pre-treated mesenchymal cells • CD34 and AC133

  18. Clinical trail • 10 patients • vastus lateralis biopsy and cells prepared and cultured • Injection + CABG • postoperative arrhythmias

  19. Surgery & Circulatory Support • Transplantation • Mechanical Assist • Biological Assist • Ventricular Containment

  20. Surgery & Circulatory Support • Transplantation • Mechanical Assist • Cardiac Support • Implantable IABP • Ventricular Assist Devices • Total Artificial Heart • Axial Flow Pump • Biological Assist • Cardiomyoplasty • Skeletal Muscle Ventricle • Ventricular Containment

  21. Ventricular containment • Cardiomyoplasty • ACORN net • Myosplint

  22. Acorn Cardiac Support Device

  23. CSD and Concommitant Proc

  24. Myosplint Change in radius R1 R2

  25. Myosplint Clinical trial • 4 patients with Myosplint • 4 patients with Myosplint + MVR • Symptomatic results unequivocal • No device related complications

  26. Mechanical assist devices Principles: • Direct systolic augmentation of the heart, • Mechanical pumping to divert blood from the left atrium/ventricle directly into the aorta with sufficient force to maintain normal arterial pressure, • Diastolic augmentation

  27. Mechanical assist devices • Pulsatile • Heartmate, LionHEART • Axial • Bearings • Jarvik 2000, Heartmate II • No Bearings • Heartmate III

  28. Implantable IABP • The Kantrowitz CardioVADTM (KCV) • 60cc pumping chamber • Percutaneous access device (PAD), • External controller • Clinical trials • 5 men (age 59 to 73)

  29. Results • Patient 1 died intra-operatively • 1 month • cardiac index increased (1.7 to 2.6 L/min/m2) • decreases in creatinine (2.6 to 1.5 mg/dL) • PCWP dec 32 to 14 mm Hg • RA dec 19 to 9 mm Hg • NYHA class improved (IV to II)

  30. Ventricular Assist Devices • Timing of LVAD intervention • Bridge-to-transplant or to-recovery • REMATCH Trial

  31. Indication for Use • Nov 2002 • FDA approved • Bridge-to-transplant • Destination therapy

  32. REMATCH Trial • 129 patients • End-stage heartfailure • NOT eligible for transplantation • LVAD 68 patients • Optimal medicalmanagement (61).

  33. Results • 48% dec in risk of death from any cause in LVAD group • Survival at oneyear 52% VS 25% (P=0.002) • Two years 23% VS 8% (P=0.09) • Adverse events risk in the device group was 2.35 times Infection, bleeding, and device malfunction

  34. Conclusions • LVAD in advanced heart failure • clinically meaningfulsurvival benefit • improved quality of life • An acceptable alternative therapy in selectedpatients • Not in candidates for cardiac transplantation

  35. Bridge-to-transplant

  36. Abiomed

  37. Heart Mate

  38. Lionheart LVAS

  39. Novocor LVAS

  40. Novocor LVAS • 1461 worldwide • Porcine valved conduit • Solenoid coil • Pusher plates

  41. Axial Flow Pump Jarvik 2000

  42. DeBakey VAD axial pump • Eur J Cardiothorac Surg. 2002 Dec, Fabiani JN. • 1999 to 2002 9 patients • NYHA functional class IV • bridge to transplantation • LV apex to ascending aorta • Mean support was 81+/-62 (16-224 days). • Eight reoperations (three for bleeding or cardiac tamponade, one for haemoperitoneum • Hemolysis in two patients. • No device infection or dysfunction • Secondary recovery in six patients. • Five patients were transplanted

  43. Rotary Blood Pump

  44. Rotary pump as RVAD

  45. Problems • Materials • Power supply • Drive line • Infection • Thrombosis • Haemorrhage • Cost • Availability

More Related